{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:12:21Z","timestamp":1794370341997,"version":"4.9.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.semarthrit.2022.151959","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T06:12:43Z","timestamp":1643609563000},"page":"151959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review"],"prefix":"10.1016","volume":"53","author":[{"given":"Mark","family":"McPherson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Economidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Liampas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Zis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Parperis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.semarthrit.2022.151959_bib0001","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/BOR.0b013e32833f1987","article-title":"Clinically amyopathic dermatomyositis","volume":"22","author":"Sato","year":"2010","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151959_bib0002","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.chest.2020.06.001","article-title":"A mortality risk score model for clinically amyopathic dermatomyositis-associated interstitial lung disease: will it have the necessary \"FLAIR\" to improve clinical outcomes?","volume":"158","author":"Baker","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2022.151959_bib0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/OARRR.S231195","article-title":"Myositis specific autoantibodies: a clinical perspective","volume":"12","author":"Alenzi","year":"2020","journal-title":"Open Access Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151959_bib0004","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/medicina57040347","article-title":"Management of myositis-associated interstitial lung disease","volume":"57","author":"Fujisawa","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.semarthrit.2022.151959_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222060","article-title":"Clinically amyopathic dermatomyositis associated with anti-MDA5 antibody","author":"Parperis","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151959_bib0006","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151959_bib0007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2022.151959_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151959_bib0009","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00296-019-04398-2","article-title":"Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review","volume":"39","author":"Huang","year":"2019","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151959_bib0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151959_bib0011","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151959_bib0012","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of myositis-related interstitial lung disease","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151959_bib0013","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"MEDRA5 (Spanish MDA5 Register) group (listed contributors at the end of the article). Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151959_bib0014","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.151959_bib0015","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2022.151959_bib0016","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151959_bib0017","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","article-title":"A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies","volume":"54","author":"Gerami","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151959_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151959_bib0019","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151959_bib0020","first-page":"123","article-title":"Primary cutaneous CD4+ small\/medium pleomorphic T-cell lymphoproliferative disorder: where do we stand? A systematic review","volume":"17","author":"Salah","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151959_bib0021","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151959_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151959_bib0023","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/03009742.2017.1334814","article-title":"Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review","volume":"47","author":"Hoa","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151959_bib0024","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0961203316651748","article-title":"Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease","volume":"25","author":"Nakashima","year":"2016","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151959_bib0025","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151959_bib0026","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-021-01705-8","article-title":"Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients","volume":"16","author":"Yang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.semarthrit.2022.151959_bib0027","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00296-021-04819-1","article-title":"Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry","volume":"41","author":"Mehta","year":"2021","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151959_bib0028","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin a to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"10.1016\/j.semarthrit.2022.151959_bib0029","first-page":"S225","article-title":"Clinical features and treatment of dermatomyositis patients with anti-CADM-140 (melanoma differentiation-associated protein 5: MDA5) antibody: recommendation of combined immunosuppressive therapy with intensive intravenous cyclophosphamide","volume":"63","author":"Nakashima","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151959_bib0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151959_bib0031","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1684\/ejd.2019.3634","article-title":"Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease","volume":"29","author":"Motegi","year":"2019","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151959_bib0032","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1346-8138.15274","article-title":"Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis","volume":"47","author":"Matsuda","year":"2020","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151959_bib0033","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.151959_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105983","article-title":"Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis \/dermatomyositis associated ILD","volume":"172","author":"Mao","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2022.151959_bib0035","doi-asserted-by":"crossref","first-page":"33226","DOI":"10.1038\/srep33226","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151959_bib0036","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151959_bib0037","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","article-title":"Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy","volume":"59","author":"Abe","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151959_bib0038","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12890-017-0479-2","article-title":"Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias","volume":"17","author":"Okabayashi","year":"2017","journal-title":"BMC Pulm Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151959_bib0039","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151959_bib0040","first-page":"1527","article-title":"Corticosteroid resistant interstitial pneumonitis in dermatomyositis\/polymyositis: prediction and treatment with cyclosporine","volume":"26","author":"Nawata","year":"1999","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151959_bib0041","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","article-title":"Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis","volume":"46","author":"Yamasaki","year":"2007","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.151959_bib0042","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","article-title":"Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease","volume":"36","author":"Go","year":"2016","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151959_bib0043","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151959_bib0044","first-page":"1719","article-title":"Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"32","author":"Kameda","year":"2005","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151959_bib0045","first-page":"254","article-title":"Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute\/subacute interstitial pneumonia in dermatomyositis","volume":"35","author":"Kotani","year":"2008","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151959_bib0046","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1097\/CCM.0b013e3181bc7bd5","article-title":"Why we should be wary of single-center trials","volume":"37","author":"Bellomo","year":"2009","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151959_bib0047","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s11606-019-04976-x","article-title":"How Often Do Systematic Reviews Exclude Articles Not Published in English?","volume":"34","author":"Jackson","year":"2019","journal-title":"J Gen Intern Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:07:49Z","timestamp":1758733669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":47,"alternative-id":["S0049017222000105"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151959","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151959","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151959"}}